Impact of HIV-1 viral subtype on CD4+ T-cell decline and clinical outcomes in antiretroviral naive patients receiving universal healthcare

AIDS

Volumn 23, Issue 6, 2009, Pages 731-737

  Keller, Marina ^a   Lu, Ying ^a   Lalonde, Richard G ^a   Klein, Marina B ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Africa; Antiretroviral naive; CD4, disease progression, haiti, hiv sequence variability subtypes

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AFRICA; ARTICLE; CANADA; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; FEMALE; HAITI; HEALTH CARE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMIGRANT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOCIOECONOMICS; VIRUS TYPING;

ADOLESCENT; ADULT; AFRICA SOUTH OF THE SAHARA; AFRICAN CONTINENTAL ANCESTRY GROUP; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CONFOUNDING FACTORS (EPIDEMIOLOGY); DISEASE PROGRESSION; FEMALE; HAITI; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; QUEBEC; YOUNG ADULT;

EID: 64549117838     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328326f77f     Document Type: Article

References (30)

1. AIDS epidemic update: special report on HIV/AIDS: December 2006. In: United Nations programme on HIV/AIDS publications; 2006. pp. 1-96.
2. Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM. The challenge of HIV-1 subtype diversity. N Engl J Med 2008; 358:1590-1602.
3. Huang W, Eshleman SH, Toma J, Fransen S, Stawiski E, Paxinos EE, et al. Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J Virol 2007; 81:7885-7893.
4. Kaleebu P, Nankya IL, Yirrell DL, Shafer LA, Kyosiimire- Lugemwa J, Lule DB, et al. Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort. J Acquir Immune Defic Syndr 2007; 45:28-33.
5. Ndung'u T, Sepako E, McLane MF, Chand F, Bedi K, Gaseitsiwe S, et al. HIV-1 subtype C in vitro growth and coreceptor utilization. Virology 2006; 347:247-260.
6. Chohan B, Lang D, Sagar M, Korber B, Lavreys L, Richardson B, Overbaugh J. Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter VI-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol 2005; 79:6528- 6531.
7. Hu DJ, Vanichseni S, Mastro TD, Raktham S, Young NL, Mock PA, et al. Viral load differences in early infection with two HIV- 1 subtypes. AIDS 2001; 15:683-691.
8. Kiwanuka N, Laeyendecker O, Robb M, Kigozi G, Arroyo M, McCutchan F, et al. Effect of human immunodeficiency virus type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis 2008; 197:707-713.
9. Kanki PJ, Hamel DJ, Sankale JL, Hsieh C, Thior I, Barin F, et al. Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis 1999; 179:68-73.
10. Lutalo T, Gray RH, Wawer M, Sewankambo N, Serwadda D, Laeyendecker O, et al. Survival of HIV-infected treatment- naive individuals with documented dates of seroconversion in Rakai, Uganda. AIDS 2007; 21 (Suppl 6):S15-S19.
11. Vasan A, Renjifo B, Hertzmark E, Chaplin B, Msamanga G, Essex M, et al. Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis 2006; 42:843-852.
12. Kaleebu P, Ross A, Morgan D, Yirrell D, Oram J, Rutebemberwa A, et al. Relationship between HIV-1 Env subtypes A and D and disease progression in a rural Ugandan cohort. AIDS 2001; 15:293-299.
13. Baeten JM, Chohan B, Lavreys L, Chohan V, McClelland RS, Certain L, et al. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis 2007; 195:1177-1180.
14. Del Amo J, Petruckevitch A, Phillips A, Johnson AM, Stephenson J, Desmond N, et al. Disease progression and survival in HIV-1-infected Africans in London. AIDS 1998; 12:1203-1209.
15. Alaeus A, Lidman K, Bjorkman A, Giesecke J, Albert J. Similar rate of disease progression among individuals infected with HIV-1 genetic subtypes A-D. AIDS 1999; 13: 901-907.
16. Akinsete OO, Sides T, Hirigoyen D, Cartwright C, Boraas C, Davey C, et al. Demographic, clinical, and virologie characteristics of African-born persons with HIV/AIDS in a Minnesota hospital. AIDS Patient Care STDS 2007; 21: 356-365.
17. Akouamba BS, Viel J, Charest H, Merindol N, Samson J, La- pointe N, et al. HIV-1 genetic diversity in antenatal cohort, Canada. Emerg Infect Dis 2005; 11:1230-1234.
18. Lepri AC, Sabin CA, Pezzotti P, England PD, Phillips AN, Rezza G. Is there a general tendency for CD4 lymphocyte decline to speed up during human immunodeficiency virus infection? Evidence from the Italian Seroconversion Study. J Infect Dis 1997; 175:775-780.
19. Tableaux sur I'immigration au Quebec; http://www.micc.gouv.qc.ca/fr/ recherches-statistiques/stats-immigration-recente. html; 13 November 2008.
20. Zencovich M, Kennedy K, MacPherson DW, Gushulak BD. Immigration medical screening and HIV infection in Canada. Int J STD AIDS 2006; 17:813-816.
21. Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE, van Steenwijk RP, et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol1992; 66:1354-1360.
22. Koot M, Keet IP, Vos AH, de Goede RE, Roos MT, Coutinho RA, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993; 118:681-688.
23. Koot M, van Leeuwen R, de Goede RE, Keet IP, Danner S, Eeftinck Schattenkerk JK, et al. Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. J Infect Dis 1999; 179:254-258.
24. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, Stanfield RL, et al. Structure of a V3-containing HIV-1 gp120 core. Science 2005; 310:1025-1028.
25. Cornelissen M, van den Burg R, Zorgdrager F, Lukashov V, Goudsmit J. pol gene diversity of five human immunodefi ciency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D. J Virol 1997; 71:6348-6358.
26. Lindsay C. The African community in Canada. In: Profiles of ethnic communities in Canada. Ottawa: Statistics Canada; 2007. pp. 1-17.
27. Chew CB, Herring BL, Zheng F, Browne C, Saksena NK, Cunningham AL, Dwyer DE. Comparison of three commercial assays for the quantification of HIV-1 UNA in plasma from individuals infected with different HIV-1 subtypes. J Clin Virol 1999; 14:87-94.
28. Holguin A, Lopez M, Molinero M, Soriano V. Performance of three commercial viral load assays, Versant human immunodeficiency virus type 1 (HIV-1) RNA bDNA v3.0, Cobas Am-pliPrep/Cobas TaqMan HIV-1, and NucliSens HIV-1 EasyQ v1.2, testing HIV-1 non-B subtypes and recombinant variants. J Clin Microbiol 2008; 46:2918-2923.
29. Lugada ES, Mermin J, Kaharuza F, Ulvestad E, Were W, Lange- land N, et al. Population-based hematologic and immunologic reference values for a healthy Ugandan population. Clin Diagn Lab Immunol 2004; 11:29-34.
30. Guidelines for the use of antiretroviral agents in HIV-1- infected adults and adolescents. In: Panel on antiretroviral guidelines for adults and adolescents. Department of Health and Human Services; 2008. pp. 1-128.